John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA-2).
Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, discusses phase III study findings on daratumumab plus bortezomib, melphalan, and prednisone vs bortezomib, melphalan, and prednisone in patients ineligible for transplant who have been newly diagnosed with multiple myeloma (Abstract LBA-4).
Carla Casulo, MD, of the James P. Wilmot Cancer Center, discusses findings on POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma, using data from more than 5,000 patients in 13 clinical trials (Abstract 412).
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency and University of British Columbia, discusses long-term results of PET-guided radiation therapy in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP (Abstract 823).
Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a high rate of complete responses and MRD negativity with durable remissions beyond 4 years (Abstract 154).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephen J. Schuster, MD, of the Abramson Cancer Center, University of Pennsylvania, discuss phase II findings on tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma (Abstract 577).
